EGFR-IN-173 是一种具有口服活性的泛突变 EGFR 酪氨酸激酶抑制剂,靶向 EGFR 19del、L858R/T790M 和 C797S 三重突变,可有效抑制 EGFR19del/T790M/C797S 突变体(IC50 = 1.19 nM),其对突变型 EGFR 的选择性较野生型高出 100 倍以上(野生型 IC50 = 19.362 μM),并能显著抑制细胞迁移、诱导非小细胞肺癌 (NSCLC) 细胞凋亡 (apoptosis)、抑制 EGFR 磷酸化及下游通路 (MAPK/ERK、AKT、STAT3),同时在 NSCLC 和 Ba/F3 异种移植模型中表现出抗肿瘤作用,可用于 NSCLC 研究。
EGFR-IN-173
产品编号: MS-I26976 分子式: C28H36ClN8O2P 分子量: 583.06
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

EGFR-IN-173 是一种具有口服活性的泛突变 EGFR 酪氨酸激酶抑制剂,靶向 EGFR 19del、L858R/T790M 和 C797S 三重突变,可有效抑制 EGFR19del/T790M/C797S 突变体(IC50 = 1.19 nM),其对突变型 EGFR 的选择性较野生型高出 100 倍以上(野生型 IC50 = 19.362 μM),并能显著抑制细胞迁移、诱导非小细胞肺癌 (NSCLC) 细胞凋亡 (apoptosis)、抑制 EGFR 磷酸化及下游通路 (MAPK/ERK、AKT、STAT3),同时在 NSCLC 和 Ba/F3 异种移植模型中表现出抗肿瘤作用,可用于 NSCLC 研究。

生物实验数据

生物活性 EGFR-IN-173 is an orally active pan-mutant EGFR tyrosine kinase inhibitor that targets EGFR 19del, L858R/T790M, and C797S triple mutations, effectively inhibiting the EGFR19del/T790M/C797S mutant with an IC50 of 1.19 nM and exhibiting more than 100-fold selectivity for mutant EGFR over wild-type EGFR (wild-type IC50 = 19.362 μM); it significantly inhibits cell migration, induces apoptosis in non-small cell lung cancer (NSCLC) cells, suppresses EGFR phosphorylation and downstream pathways (MAPK/ERK, AKT, STAT3), demonstrates antitumor effects in NSCLC and Ba/F3 xenograft models, and can be used for NSCLC research.
体外研究
(In Vitro)

EGFR-IN-173 (compound D10) (0.001-20 μM,72 小时) 对多种 EGFR 突变体表现出广泛而强大的抗增殖活性,在 HCC827 细胞 (EGFR19del) 中的 IC50 值为 0.69 nM,在 H1975 细胞 (EGFRL858R/T790M) 中为 0.242 μM,在 Ba/F3-EGFR19del/T790M/C797S 细胞中为 0.192 μM,在 Ba/F3-EGFRL858R/T790M/C797S 中为 1.303 μM,并对突变 EGFR 表现出超过 100 倍的选择性 (野生型 IC50 = 19.362 μM)。
EGFR-IN-173 占据 EGFR 的活性位点,并与 Lys728 和 Ser797 形成重要的氢键。
EGFR-IN-173 (10-100 nM,14 天) 剂量依赖性地抑制非小细胞肺癌 HCC827 细胞的集落形成,从而抑制其长期增殖能力。
EGFR-IN-173 (10-100 nM,0-48 小时) 以浓度依赖性方式有效抑制非小细胞肺癌 H1975 细胞的迁移。
EGFR-IN-173 (20-200 nM,48 小时) 在 HCC827 细胞中诱导 G0/G1 期阻滞,且呈剂量依赖性。
EGFR-IN-173 (1-2000 nM,48 小时) 通过触发标志性形态学事件 (包括染色质凝聚、核碎裂和凋亡小体的形成),以浓度依赖性方式诱导早期和晚期细胞凋亡。
EGFR-IN-173 (0.01-1 μM,48 小时) 能剂量依赖性地抑制 EGFR 磷酸化并抑制下游通路 (MAPK/ERK、AKT、STAT3),最终触发细胞凋亡和 ERK1/2 等信号蛋白的降解。

Western Blot Analysis

Cell Line: HCC827 cells and H1975-OR cells
Concentration: 0.01, 0.1 and 1 μM
Incubation Time: 48 h
Result: Exhibited superior dose-responsive inhibition of EGFR autophosphorylation at Tyr1068, a key molecular switch for downstream pathway activation.
Suppressed ERK1/2 phosphorylation (T202/Y204, T185/Y187) at 0.1 μM with 35.6 % inhibition, demonstrating potent blockade of the MAPK signaling axis.
Almost completely abrogated EGFR activation at 1 μM, whereas BLU-945 (MS-L43671) showed weak inhibition at an equivalent concentration in HCC827 cells.
Significantly reduced ERK1/2 protein level at 100 nM.
Reduced p-Stat3 (Tyr705), p-Akt (Ser473), and p-Mek1/2 (Ser217/221) levels.
Increased cleaved caspase-3 at 100 nM, suggesting that the concurrent downregulation of ERK1/2 resulted from apoptosis-induced protein degradation.
Suppressed EGFR phosphorylation in H1975-OR cells at 100 nM.

Cell Migration Assay

Cell Line: H1975 cells
Concentration: 10 and 100 nM
Incubation Time: 0, 24 and 48 h
Result: Significantly decreased wound closure compared to the negative control, indicating a dose-dependent inhibition of cell migration.
Resulted in a significantly larger wound area than the control over time.

Cell Cycle Analysis

Cell Line: HCC827 cells
Concentration: 20 and 200 nM
Incubation Time: 48 h
Result: Dose-dependently accumulated cells in the G0/G1 phase, increasing the population from 74.40% at 20 nM to 94.58% at 200 nM.
Induced G0/G1 phase cell cycle arrest (94.58 %) comparable to Osimertinib (MS-Q22788) (94.92 %) at 200 nM.

Apoptosis Analysis

Cell Line: HCC827 and H1975 cells
Concentration: 20, 200, and 2000 nM (H1975 cells, DAPI Staining); 20, 200, and 2000 nM (HCC827 cells, AO/EB Staining); 1, 10, and 100 nM (HCC827 cells, Hoechst 33342/PI Staining); 10, 100, and 1000 nM (HCC827 cells, Flow Cytometry)
Incubation Time: 48 h
Result: Induced dose-dependent nuclear condensation and fragmentation, with more pronounced effects than Osimertinib at equivalent concentrations.
Triggered nuclear condensation in HCC827 cells at 20 nM.
Induced a progressive rise in late-stage apoptosis in a concentration-dependent manner.
Exhibited concentration-dependent chromatin condensation and subsequent nuclear fragmentation, both hallmarks of apoptosis.
Induced the formation of apoptotic bodies.
Resulted in 6.36 %, 19.9 % and 31.6 % early apoptosis at 10, 100 and 1000 nM.

Cell Proliferation Assay

Cell Line: HCC827 cells
Concentration: 10, 50 and 100 nM
Incubation Time: 14 days
Result: Dose-dependently suppressed colony formation, exhibiting 32.8 % inhibition at 10 nM compared to the control.
Showed 58.3 % inhibition at 50 nM and nearly complete suppression at 100 nM.
体内研究
(In Vivo)

EGFR-IN-173 (25 和 50 mg/kg,口服给药,每日一次,持续 12 天) 在 HCC827 异种移植瘤小鼠模型中表现出显著的抑制肿瘤生长作用。
EGFR-IN-173 ( 50 mg/kg,口服给药,每日一次,持续 17 天) 在 Ba/F3-EGFR19del/T790M/C797S 异种移植瘤小鼠模型中对 EGFR19del/T790M/C797S 三重突变表现出一定的抑制作用。

Animal Model: Female BALB/c nude mice, (6-8 weeks) subcutaneously injected with Ba/F3-EGFR19del/ T790M/C797S cells
Dosage: 50 mg/kg
Administration: P.O., daily for 17 days
Result: Significantly reduced tumor volume and weight compared to the vehicle control group.
Reduced tumor cell density and increased intertumoral fibrosis.
Exhibited no significant body weight loss during the dosing period.
Animal Model: Male BALB/c nude mice (6-8 weeks) subcutaneously injected with HCC827 cells
Dosage: 25 and 50 mg/kg
Administration: P.O., daily for 12 days
Result: Significantly suppressed tumor growth and reduced excised tumor weight at both low and high doses, demonstrating its potent efficacy and favorable dose tolerance.
Exhibited no significant body weight loss or clinically observable adverse effects at the dose of 50 mg/kg, supporting a favorable safety profile with minimal systemic toxicity.

化学信息

分子量 583.06
分子式 C28H36ClN8O2P

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础